BioNTech SE reported growth in earnings and revenue for the fourth quarter, driven by the Covid-19 vaccine it produces in partnership with Pfizer Inc. The company also announced its program for repurchasing shares of up to $1.5 billion over the next two years.
The company posted net profit of 3.17 billion euros ($3.51 billion) for the last quarter of the year, up from EUR3.66 million a year prior. Operating income rose to EUR4.70 billion from EUR244 million in the fourth quarter of 2020.
Revenue rose to EUR5.53 billion from EUR345 million.
New Covid-19 vaccine orders for 2022 increased to 2.4 billion doses. It expects revenue from the shot to range between EUR13 billion and EUR17 billion this year.
BionTech will propose a special cash dividend of EUR2 a share at the annual general meeting.